Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)
Status:
Terminated
Trial end date:
2018-11-09
Target enrollment:
Participant gender:
Summary
This pilot study will assess the impact of sacubitril/valsartan (trade name Entresto) on the
elevated pulmonary artery pressures in patients with heart failure with reduced ejection
fraction, measured using a previously implanted hemodynamic monitoring device (CardioMEMS).
Phase:
Phase 4
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
Novartis
Treatments:
Angiotensin II Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists Angiotensin-Converting Enzyme Inhibitors Angiotensinogen Enzyme Inhibitors Giapreza LCZ 696 Valsartan